Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors (NETs).

Somatostatin analogs, a synthetic hormone therapy, have been a standard treatment for NETs, Liu explains, while a new somatostatin analog, somatuline, has also been shown to slow tumor growth. Additional recently approved agents for pancreatic NETS include sunitinib and everolimus.

Liu mentions other agents that are pushing the field forward, including telotristat etiprate for the treatment of carcinoid syndrome, and Lutathera, described as a radioactive version of octreotide, also shown to slow tumor growth.

Videos

Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors.

Eric Liu, MD, FACS

Articles

Dr. Liu on Medical Advancements for Neuroendocrine Tumors